(Reuters) - CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give the hepatitis C treatment from Gilead Sciences Inc preferred status and cover a new competing treatment from AbbVie Inc only as an exception, CNBC reported on Monday.
via Reuters: Health News Read More Here..
via Reuters: Health News Read More Here..
No comments:
Post a Comment